Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Advances in the delivery of buprenorphine for opioid dependence.

Rosenthal RN, Goradia VV.

Drug Des Devel Ther. 2017 Aug 28;11:2493-2505. doi: 10.2147/DDDT.S72543. eCollection 2017. Review.

2.

Characteristics and Treatment of Patients with Clinical Illness Due to Synthetic Cannabinoid Inhalation Reported by Medical Toxicologists: A ToxIC Database Study.

Monte AA, Calello DP, Gerona RR, Hamad E, Campleman SL, Brent J, Wax P, Carlson RG; ACMT Toxicology Investigators Consortium (ToxIC).

J Med Toxicol. 2017 Jun;13(2):146-152. doi: 10.1007/s13181-017-0605-9. Epub 2017 Apr 10.

PMID:
28397128
3.

Taking adolescent prescription opioid use in context: risk stratification in early mid-life based on medical and nonmedical use.

Hah J.

Pain. 2016 Oct;157(10):2143-4. doi: 10.1097/j.pain.0000000000000655. No abstract available.

4.

Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study.

Carlson RG, Nahhas RW, Martins SS, Daniulaityte R.

Drug Alcohol Depend. 2016 Mar 1;160:127-34. doi: 10.1016/j.drugalcdep.2015.12.026. Epub 2016 Jan 4.

5.

Acute Pain Medicine in the United States: A Status Report.

Tighe P, Buckenmaier CC 3rd, Boezaart AP, Carr DB, Clark LL, Herring AA, Kent M, Mackey S, Mariano ER, Polomano RC, Reisfield GM.

Pain Med. 2015 Sep;16(9):1806-26. doi: 10.1111/pme.12760. Epub 2015 Jun 10.

6.

Dynamic model of nonmedical opioid use trajectories and potential policy interventions.

Wakeland W, Nielsen A, Geissert P.

Am J Drug Alcohol Abuse. 2015;41(6):508-18. doi: 10.3109/00952990.2015.1043435. Epub 2015 May 18.

7.

Pain management perceptions among prescription opioid dependent individuals.

McCauley JL, Mercer MA, Barth KS, Brady KT, Back SE.

Drug Alcohol Depend. 2014 Sep 1;142:354-8. doi: 10.1016/j.drugalcdep.2014.06.024. Epub 2014 Jun 25.

8.

Self-loathing aspects of depression reduce postoperative opioid cessation rate.

Hah JM, Mackey S, Barelka PL, Wang CK, Wang BM, Gillespie MJ, McCue R, Younger JW, Trafton J, Humphreys K, Goodman SB, Dirbas FM, Schmidt PC, Carroll IR.

Pain Med. 2014 Jun;15(6):954-64. doi: 10.1111/pme.12439.

9.

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.

Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM.

Pharmacoepidemiol Drug Saf. 2014 Dec;23(12):1238-46. doi: 10.1002/pds.3658. Epub 2014 Jun 11.

10.
11.

Formulation optimization of hot-melt extruded abuse deterrent pellet dosage form utilizing design of experiments.

Maddineni S, Battu SK, Morott J, Soumyajit M, Repka MA.

J Pharm Pharmacol. 2014 Feb;66(2):309-22. doi: 10.1111/jphp.12129. Epub 2013 Aug 20.

12.

Latent class analysis of non-opioid dependent illegal pharmaceutical opioid users in Ohio.

Carlson RG, Nahhas RW, Daniulaityte R, Martins SS, Li L, Falck R.

Drug Alcohol Depend. 2014 Jan 1;134:259-266. doi: 10.1016/j.drugalcdep.2013.10.004. Epub 2013 Oct 23.

13.

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.

Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD.

Pharmacoepidemiol Drug Saf. 2013 Dec;22(12):1274-82. doi: 10.1002/pds.3522. Epub 2013 Sep 30.

14.

Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.

Schaeffer T.

J Med Toxicol. 2012 Dec;8(4):400-7. doi: 10.1007/s13181-012-0270-y. Review.

15.

Epidemiology of pain among outpatients in methadone maintenance treatment programs.

Dhingra L, Masson C, Perlman DC, Seewald RM, Katz J, McKnight C, Homel P, Wald E, Jordan AE, Young C, Portenoy RK.

Drug Alcohol Depend. 2013 Feb 1;128(1-2):161-5. doi: 10.1016/j.drugalcdep.2012.08.003. Epub 2012 Aug 27.

16.
17.

Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release.

Benedek IH, Jobes J, Xiang Q, Fiske WD.

Drug Des Devel Ther. 2011;5:455-63. doi: 10.2147/DDDT.S24372. Epub 2011 Nov 23.

18.

Typologies of prescription opioid use in a large sample of adults assessed for substance abuse treatment.

Green TC, Black R, Grimes Serrano JM, Budman SH, Butler SF.

PLoS One. 2011;6(11):e27244. doi: 10.1371/journal.pone.0027244. Epub 2011 Nov 2.

19.

Characteristics and correlates of men and women with prescription opioid dependence.

Back SE, Lawson KM, Singleton LM, Brady KT.

Addict Behav. 2011 Aug;36(8):829-34. doi: 10.1016/j.addbeh.2011.03.013. Epub 2011 Mar 25.

20.

Route of administration for illicit prescription opioids: a comparison of rural and urban drug users.

Young AM, Havens JR, Leukefeld CG.

Harm Reduct J. 2010 Oct 15;7:24. doi: 10.1186/1477-7517-7-24.

Supplemental Content

Support Center